Avalo Therapeutics, Inc.: STATE STREET CORP discloses a stake of more than 5% (Schedule 13G)
Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 10 November 2026, by SEC EDGAR SCHEDULE 13G
30
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
State Street Corp. disclosed a stake exceeding 5% in Avalo Therapeutics Inc. via a Schedule 13G filing with the SEC (accession 0000093751-26-000620). The passive-investor disclosure signals heightened institutional ownership in the clinical-stage biopharmaceutical company. The exact share count and percentage were not specified in the filing headline. Investors will watch for further 13G amendments and quarterly 13F updates for precise position sizing.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
State Street Corp, Avalo Therapeutics, Inc.